The accompanying notes are an integral part of the unaudited financial statements.
The accompanying notes are an integral part of the unaudited financial statements.
UNAUDITED NOTES TO THE FINANCIAL STATEMENTS (Unaudited)
Note 1 – Description of Organization and Business Operations
Organization and General
Alpha Star Acquisition Corporation (the “Company”) is a blank check company incorporated in the Cayman Islands on March 11, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). The Company has selected December 31 as its fiscal year-end.
Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on businesses that have a connection to the Asian market. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
The Company’s sponsor is A-Star Management Corporation, a British Virgin Islands incorporated company (the “Sponsor”). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering (the “IPO”).
The Company has 9 months from the closing of the IPO (or up to 21 months from the closing of our initial public offering if we extend the period of time to consummate a business combination) to consummate a Business Combination (the “Combination Period”). If the Company fails to consummate a Business Combination within the Combination Period, it will trigger its automatic winding up, liquidation and subsequent dissolution pursuant to the terms of the Company’s amended and restated memorandum and articles of association. As a result, this has the same effect as if the Company had formally gone through a voluntary liquidation procedure under the Companies Law. Accordingly, no vote would be required from the Company’s stockholders to commence such a voluntary winding up, liquidation and subsequent dissolution.
The Company’s IPO was declared effective on December 13, 2021. On December 15, 2021, the Company consummated the IPO of 11,500,000 units which includes an additional 1,500,000 units as a result of the underwriters’ fully exercise of the over-allotment, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3.
The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). The Ordinary shares subject to possible redemption, at redemption value of $10.09 and $10.00 per share for September 30, 2022 and December 31, 2021, respectively.
Concurrently with the closing of the IPO, the Company consummated the sale of 330,000 units (the “Private Placement”) at a price of $10.00 per Private Unit in a private placement to A-Star Management Corporation, generating gross proceeds of $3,300,000, which is described in Note 4.
On September 13, 2022, the Company announced that
it has entered into a non-binding letter of intent (“LOI”) for a business combination with Cyclebit Group (the “Cyclebit”).
Founded in 2012, Cyclebit is a global payments and SaaS provider. Its core products include card acquiring, point-of-sale (POS) services
and marketplace solutions. Under the terms of the LOI, the Company and Cyclebit would become a combined entity, with the Cyclebit’s
existing equity holders rolling 100% of their equity into the combined public company. The Company expects to announce additional details
regarding the proposed business combination when a definitive agreement is executed, which is expected in the fourth quarter of 2022.
No assurance can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction
will be consummated on the terms or time frame currently contemplated, or at all. Any transaction would be subject to board an equity
holder approval of both companies, regulatory approvals and other customary conditions.
The Trust Account
As of December 15, 2021, a total of $115,682,250 of the net proceeds from the IPO and the Private Placement transaction completed with the Sponsor was deposited in a trust account established for the benefit of the Company’s public stockholders with Wilmington Trust, National Association acting as trustee. The amount exceeding $115,000,000, $682,254, had been transfer to the Company’s escrow cash account as its working capital. At September 30, 2022, the Company had working capital deficiencies of $378,781, which excludes $116,077,245 of marketable securities held in the trust account and the liability for deferred underwriting commissions of $2,875,000.
The funds held in the Trust Account are invested only in United States government treasury bills, bonds or notes having a maturity of 180 days or less, or in money market funds meeting the applicable conditions under Rule 2a-7 promulgated under the Investment Company Act of 1940 and that invest solely in United States government treasuries. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income or other tax obligations, the proceeds will not be released from the Trust Account until the earlier of the completion of a Business Combination or the Company’s liquidation.
Liquidity and Going Concern
As of September 30, 2022, the Company had cash $130,166 in its escrow account and working capital deficiencies of $378,781, which excludes $116,077,245 of marketable securities held in the trust account and the liability for deferred underwriting commissions of $2,875,000.
The Company’s liquidity needs to date have been satisfied through a payment of $25,000 from the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares and the proceeds from the consummation of the Private Placement not held in the Trust Account to provide working capital needed to identify and seek to consummate a Business Combination.
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company related party loans up to $1,500,000. As of September 30, 2022, the Company had no convertible loan payable balance.
If the Company’s estimate of the costs of identifying a target business, undertaking due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate our business prior to our initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete its Business Combination or because the Company has become obligated to redeem a significant number of its Public Shares upon completion of its Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. In addition, we have until September 15, 2023 (the “Liquidation Date”) to consummate a business combination.
In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Codification (“ASC”) 205-40, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unable to complete a Business Combination by the Liquidation Date, then the Company may cease all operations except for the purpose of liquidating. The uncertainty surrounding the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. Management expects to close the Business Combination prior to the Liquidation Date. If the Company is unable to close the Business Combination or raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily include or be limited to, curtailing operations, suspending the pursuit of a potential transaction and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms or if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern through the Liquidation Date if a Business Combination is not consummated.
Management
believes that, on September 30, 2022, the Company will has insufficient working capital to cover its short-term operating needs.
The Company only has interest income earned from the investment held in trust and restricted to use before the Business Combination.
Its business plan is dependent on the completion of a financing transaction and the Company’s cash and working capital as
of September 30, 2022 are not sufficient to complete its planned activities for the upcoming year. As the Company in order to
extend the time to conclude the business combination, the Company was requiring to pay the transaction costs and extension
fees and deposit into the trust account. The capital funding will be provided by the sponsor as promissory notes. The deposit
amount is $383,333 and require to pay by monthly. The Promissory note that the Company and the Sponsor entered during
the third quarter with the maximum principal $1,000,000. There is going concern issues that the Company will not have
sufficient liquidity to meet its probable cash needs over the next 12 months. These factors raise substantial doubt about the
Company’s ability to continue as a going concern one year from the date the financial statement is issued.
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements of the Company are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).
These unaudited financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Annual Report for the year ended December 31, 2021, which are included in Form 10-K filed on March 30, 2022.
Emerging Growth Company
The Company is an emerging growth company as defined by Section 2(a) of the JOBS Act and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but no limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosures obligations regarding executive compensation in its periodic reports and proxy statements, and exceptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payment not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statement in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The initial valuation of the public warrants and private warrants (as defined in Note 7) and ordinary shares subject to redemption required management to exercise significant judgement in its estimates. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $130,166 and $387,858 cash held in escrow and did not have any cash equivalents as of September 30, 2022 and December 31, 2021, respectively.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. As of September 30, 2022 and December 31, 2021, the Company had not experienced losses on this account respectively.
Marketable Securities Held in Trust Account
The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned and unrealized gain on marketable securities held in Trust Account in the accompanying statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. The Company had $116,077,245 and $115,000,744 of marketable securities held in the trust account, and have no claim to withdraw or distribute any funds from the trust account as of September 30, 2022 and December 31, 2021, respectively.
Offering Costs Associated with the Initial Public Offering
Offering costs consist of underwriting, legal, accounting, registration and other expenses incurred through the balance sheet date that are directly related to the IPO. As of December 15, 2021, offering costs amounted to $5,669,696 consisting of $2,300,000 of underwriting fees, $2,875,000 of deferred underwriting fees, and $494,696 of other offering costs. The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A – “Expenses of Offering”. The Company allocates offering costs between public shares, public rights and public warrants based on the estimated fair values of public shares, public warrants, and public rights at the date of issuance.
Ordinary Shares Subject to Possible Redemption
The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as stockholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.
All of the 11,500,000 ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s Certificate of Incorporation. Accordingly, all of the 11,500,000 shares of ordinary shares are presented as temporary equity.
The Company recognizes changes in redemption
value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the
end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges
against additional paid-in capital and accumulated deficit if additional paid in capital equals to zero. The interest earned by
the marketable security held in trust, and the extension fee invest into the marketable security held in trust, were also recognizes
in redemption value against additional paid-in capital and accumulated deficit immediately. The proceeds on the deposit in the trust account, including interest (which interest shall be net of taxes payable, and less up to $50,000 of interest to pay dissolution expenses) will be used to fund the redemption of the public shares.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to the short-term nature.
Net Income (Loss) per Share
The Company complies with accounting and
disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” In order to determine the net income (loss)
attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss)
allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total
net income (loss) less any dividends paid. The Company then allocated the undistributed income (loss) rateably based on the weighted
average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to
redemption value of the ordinary shares subject to possible redemption was considered to be dividends paid to the public
stockholders.
The calculation of diluted income (loss) per ordinary shares does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 5,915,000 shares of ordinary shares in the aggregate. As of September 30, 2022, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary shares is the same as basic net income (loss) per ordinary share for the periods presented.
The net income (loss) per share presented in the statement of operations is based on the following:
Schedule of statement of operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, 2022 |
|
|
For the
Three Months Ended September 30, 2021 |
|
|
For the
Nine Months Ended September 30, 2022 |
|
|
For the Period from March 11, 2021 (inception) to September 30, 2021 |
|
Net income (Loss) |
|
$ |
415,467 |
|
|
$ |
(800 |
) |
|
$ |
220,668 |
|
|
$ |
(11,850 |
) |
Remeasurement to redemption value – interest income earned |
|
|
(520,450 |
) |
|
|
|
|
|
|
(693,167 |
) |
|
|
|
|
Remeasurement to redemption value – extension fee |
|
|
(383,333 |
) |
|
|
- |
|
|
|
(383,333 |
) |
|
|
- |
|
Net loss including accretion of temporary equity to redemption value |
|
$ |
(488,316 |
) |
|
|
- |
|
|
$ |
(855,832 |
) |
|
|
- |
|
Schedule of earning per share basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, 2022 (Unaudited) |
|
|
For the Three Months Ended September 30, 2021 (Unaudited) |
|
|
For the Nine Months Ended September 30, 2022 (Unaudited) |
|
|
For the Period from March 11, 2021 (inception) to September 30, 2021 (Unaudited) |
|
|
|
Non- redeemable shares |
|
|
Redeemable shares |
|
|
Non- redeemable shares |
|
|
Redeemable shares |
|
|
Non- redeemable shares |
|
|
Redeemable shares |
|
|
Non- redeemable shares |
|
|
Redeemable shares |
|
Basic and Diluted net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Numerators: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net losses |
|
$ |
(106,430 |
) |
|
$ |
(381,886 |
) |
|
$ |
(800 |
) |
|
$ |
- |
|
|
$ |
(186,531 |
) |
|
$ |
(669,531 |
) |
|
$ |
(11,850 |
) |
|
$ |
- |
|
Accretion of extension fee |
|
|
- |
|
|
|
383,333 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
383,333 |
|
|
|
- |
|
|
|
- |
|
Accretion of temporary
equity- interest income earned |
|
|
- |
|
|
|
520,450 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
693,167 |
|
|
|
- |
|
|
|
- |
|
Allocation of net income (loss) |
|
$ |
(106,430 |
) |
|
$ |
521,897 |
|
|
$ |
(800 |
) |
|
$ |
- |
|
|
$ |
(186,531 |
) |
|
$ |
407,199 |
|
|
$ |
(11,850 |
) |
|
$ |
- |
|
Denominators: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding |
|
|
3,205,000 |
|
|
|
11,500,000 |
|
|
|
2,875,000 |
|
|
|
- |
|
|
|
3,205,000 |
|
|
|
11,500,000 |
|
|
|
2,875,000 |
|
|
|
- |
|
Basic and diluted net income (loss) per share |
|
$ |
(0.03 |
) |
|
$ |
0.05 |
|
|
$ |
(0.00 |
) |
|
$ |
- |
|
|
$ |
(0.06 |
) |
|
$ |
0.04 |
|
|
$ |
(0.00 |
) |
|
$ |
- |
|
Income Taxes
The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company has identified the Cayman Islands as its only “major” tax jurisdiction, as defined. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statement. Since the Company was incorporated on March 11, 2021, the evaluation was performed for the period ended September 30, 2022 which will be the only period subject to examination. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income tax expense.
On
August 16, 2022, the U.S. Government enacted legislation commonly referred to as the Inflation Reduction Act. The main provisions
of the Inflation Reduction Act (the “IR Act”) that we anticipate may impact us is a 1% excise tax on share repurchases.
Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote
or otherwise, may be subject to the excise tax. Because there is possibility that the Company may acquire a U.S. domestic corporation
or engage in a transaction in which a domestic corporation becomes parent or affiliate to the Company and the Company may become
a “covered corporation” as a listed Company in Nasdaq. The management team has evaluated the IR Act as
of September 30, 2022 and does not believe it would have a material effect on the Company, and will continue to evaluate
its impact.
The provision for income taxes was deemed to be immaterial for nine months ended September 30, 2022 and for the period end from March 11, 2021 to September 30, 2021.
Warrants
The Company evaluates the Public and Private Warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’ specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares, among other conditions for equity classification. Pursuant to such evaluation, both Public and Private Warrants are classified in stockholders’ equity.
Recently Issued Accounting Standards
In August
2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt
— Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s
Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates
the current models that require separation of beneficial conversion and cash conversion features from convertible instruments
and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own
equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed
to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the
requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the fiscal
years beginning after December 15, 2023, and interim periods within those fiscal year for smaller reporting companies. As of September
30, 2022, management does not believe that any recently effective, accounting pronouncements, if currently adopted, would have
a material effect on the Company’s financial statements.
Note 3 – Initial Public Offering
On December 15, 2021, the Company
consummated the initial public offering and sale of 11,500,000 units
(including the issuance of 1,500,000 units
as a result of the underwriters’ fully exercise of the over-allotment) at a price of $10.00 per
Unit, generating gross proceeds of $115,000,000.
Each Unit consists of one ordinary share, one redeemable warrant (each a “Warrant”, and, collectively, the
“Warrants”), and one right to receive one-seventh (1/7) of an ordinary share upon the consummation of a Business
Combination. Each two redeemable warrants entitle the holder thereof to purchase one ordinary share, and each seven rights
entitle the holder thereof to receive one ordinary share at the closing of a Business Combination. No fractional shares were
issued upon separation of the Units, and only whole Warrants will trade.
Note 4 – Private Placement
Concurrently with the consummation of the IPO, A-Star Management Corporation, the Sponsor, purchased an aggregate of 330,000 units at a price of $10.00 per Private Unit for an aggregate purchase price of $3,300,000 in a private placement. The Private Units are identical to the public Units except with respect to certain registration rights and transfer restrictions. The proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying securities will expire worthless.
Note 5 – Related Party Transactions
Founder Shares
On March 11, 2021, the Company issued one ordinary share to the Sponsor for no consideration. On April 6, 2021, the Company cancelled the one share for no consideration and the Sponsor purchased ordinary shares for an aggregate price of $25,000.
The 2,875,000 founder shares (for purposes hereof referred to as the “Founder Shares”) include an aggregate of up to 375,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the Sponsor will collectively own 20% of the Company’s issued and outstanding shares after the Proposed Offering. On December 15, 2021, the underwriters exercised the over-allotment option in full, so there are no Founder Shares subject to forfeiture as of September 30, 2022.
The Sponsor and each Insider agrees that
it, he or she shall not (a) Transfer 50% of their Founder Shares until the earlier of (A) six months after the consummation
of the Company’s initial Business Combination or (B) the date on which the closing price of the Ordinary Shares equals
or exceeds $12.50 per share (as adjusted for share splits, share capitalizations, rights issuances, subdivisions, reorganizations,
recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s
initial Business Combination or (b) Transfer the remaining 50% of their Founder Shares until six months after the date of
the consummation of the Company’s initial Business Combination, or earlier in either case, if subsequent to the Company’s
initial Business Combination the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction
that results in all of the Company’s stockholders having the right to exchange their Ordinary Shares for cash, securities
or other property (the “Founder
Shares Lock-up Period”).
Administrative Services Agreement
The Company entered into an administrative services agreement, commencing on December 13, 2021, through the earlier of the Company’s consummation of a Business Combination or its liquidation, to pay to the Sponsor a total of $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. From nine months ended September 30, 2022 and period end from March 11, 2021 (inception) through September 30, 2021, the Company incurred $90,000 and nil 0 in fees for these services respectively. For three months ended September 30, 2022 and 2021, the Company incurred $30,000 and nil 0 in fees for these services respectively.
Sponsor Promissory Note — Related Party
On March 26, 2021, the Company
issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal
amount of $ (the
“Promissory Note”). The Promissory Note is non-interest bearing and payable on the earlier of
(i) December 31, 2021 or (ii) the consummation of the Proposed Offering. The loan was repaid as $ allotted
to the payment of offering expense during the consummation of the Proposed Offering as of December 15, 2021.
In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete an initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units at a price of $10.00 per unit (which, for example, would result in the holders being issued 150,000 ordinary shares, 150,000 rights and 150,000 warrants to purchase 75,000 shares if $1,500,000 of notes were so converted) at the option of the lender. The units would be identical to the placement units issued to the initial holder. The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. We do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. The convertible loans from Sponsor balances were nil as of September 30, 2022 and December 31, 2021.
On September 13, 2022, the Company
issued a promissory note (the “Note”)
in the principal amount of up to $ to
the Sponsor,
pursuant to which the Sponsor shall loan to the Company up to $1,000,000 to
pay the extension fee and transaction cost. On September 13, 2022, the Company requested to draw the funds of $383,333 and
deposited it into the trust account to extend the period of time the Company has to consummate a business combination by one month
to October 15, 2022. The $383,333 extension
fee represents approximately $0.033 per
public share. The Notes bear no interest and are repayable in full upon the earlier of (a) September 15, 2023 or (b) the date
of the consummation of the Company’s initial business combination. The Note have no conversion feature, and no collateral. The
issuance of the Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of
1933, as amended. The Sponsor waives any and all right, title, interest or claim of any kind in or to any distribution of or from
the trust account, and agrees not to seek resources, reimbursement, payment or satisfaction for any claim against the trust account
for any reason whatsoever. Sponsor promissory note balances were 383,333 and nil
as of September 30, 2022 and December 31, 2021 respectively.
Note 6 – Commitments and Contingencies
Risks and Uncertainties
Management continues to evaluate the impact of
the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s
financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as
of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.
In February 2022, the Russian Federation and Belarus
commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have
instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on
the world economy is not determinable as of the date of these unaudited condensed consolidated financial statements. The specific impact
on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited
condensed consolidated financial statements. The management will continuously evaluate the effect to the Company.
Underwriters Agreement
The Company granted the underwriters, a 45-day option to purchase up to 1,500,000 Units (over and above the 10,000,000 units referred to above) solely to cover over-allotments at $10.00 per Unit. On December 15, 2021, the underwriters exercised the over-allotment option in full to purchase 1,500,000 Units at a purchase price of $10.00 per Unit.
On December 15, 2021, the Company paid a cash underwriting commission of 2.0% of the gross proceeds of the IPO, or $2,300,000.
The underwriters are entitled to a deferred underwriting commission of 2.5% of the gross proceeds of the IPO, or $2,875,000, which will be paid from the funds held in the Trust Account upon completion of the Company’s initial Business Combination subject to the terms of the underwriting agreement. The Company has the deferred underwriting commissions $2,875,000 and $2,875,000 as current liabilities as of September 30, 2022 and December 31, 2021, respectively.
Registration Rights
The holders of the Founder Shares will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the IPO. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Note 7 – Stockholders’ Deficit
Ordinary Shares
The Company is authorized to issue 50,000,000 ordinary shares, with a par value of $0.001 per share. Holders of the ordinary shares are entitled to one vote for each ordinary share. At September 30, 2022, there were 3,205,000 ordinary shares issued and outstanding, excluding 11,500,000 shares subject to possible redemption. The Sponsor has agreed to forfeit 375,000 ordinary shares to the extent that the over-allotment option is not exercised in full by the underwriters. On December 15, 2021, the underwriters fully exercised the over-allotment option, as such there are no ordinary shares subject to forfeiture. The Company’s historical stockholders’ equity was retrospectively restated to the first period, January 1, 2021, the amount of shares to the Company by the Sponsor for $ at par value $0.0001, with additional paid-in capital $ in April 2021, includes of up to 375,000 shares subject to forfeiture, as over-allotment option is fully exercised by the underwriters.
Public Warrants
Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a price of $10.00 per Unit for a total of $115,000,000. The total amount of ordinary shares subject to possible redemption is 11,500,000. Each Unit consists of one ordinary share, one right to acquire one-seventh (1/7) of an ordinary share, and one redeemable warrant (“Public Warrant”) to purchase one-half of one ordinary share at a price of $11.50 per share, subject to adjustment. As of September 30, 2022 and December 31, 2021, the Company had 11,500,000 public warrants outstanding.
Each warrant entitles the holder to purchase one-half ordinary share at a price of $11.50 per share commencing 30 days after the completion of its initial business combination and expiring five years from after the completion of an initial business combination. No fractional warrant will be issued and only whole warrants will trade. The Company may redeem the warrants at a price of $0.01 per warrant upon 30 days’ notice, only in the event that the last sale price of the ordinary shares is at least $18.00 per share for any 20 trading days within a 30-trading day period ending on the third day prior to the date on which notice of redemption is given, provided there is an effective registration statement and current prospectus in effect with respect to the ordinary shares underlying such warrants during the 30 day redemption period. If a registration statement is not effective within 60 days following the consummation of a business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act.
In addition, if (a) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors), (b) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination, and (c) the volume weighted average trading price of the ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value, and the last sales price of the ordinary shares that triggers the Company’s right to redeem the Warrants will be adjusted (to the nearest cent) to be equal to 180% of the Market Value.
Private warrants
The private warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in this offering. As of September 30, 2022 and December 31, 2021, the Company had 330,000 private warrants outstanding.
Rights
Except in cases where the Company is not the surviving Company in a business combination, the holders of the rights will automatically receive 1/7 of a share of ordinary shares upon consummation of the Company’s initial business combination. In the event the Company will not be the surviving company upon completion of the initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the 1/7 of a share underlying each right upon consummation of the business combination. As of September 30, 2022, no rights had been converted into shares.
Note 8 – Fair Value Measurements
The Company complies with ASC 820, “Fair Value Measurements”, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. ASC 820 determines fair value to be the price that would be received to sell an asset or would be paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date.
The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2: Observable inputs other than Level inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
At September 30, 2022 and December 31, 2021, assets held in the trust account were entirely comprised of marketable securities.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.
Schedule of fair value measured on a recurring basis |
|
|
|
|
|
|
|
|
|
|
|
|
Assets September 30, 2022 |
|
Quoted Prices in Active Markets (Level 1) |
|
|
Significant Other Observable Inputs (Level 2) |
|
|
Significant Other Unobservable Inputs (Level 3) |
|
Marketable Securities held in Trust Account |
|
$ |
116,077,245 |
|
|
$ |
- |
|
|
$ |
- |
|
Assets December 31, 2021 |
|
Quoted Prices in Active Markets (Level 1) |
|
|
Significant Other Observable Inputs (Level 2) |
|
|
Significant Other Unobservable Inputs (Level 3) |
|
Marketable Securities held in Trust Account |
|
$ |
115,000,744 |
|
|
$ |
- |
|
|
$ |
- |
|
Note 9 – Subsequent Events
The Company evaluated subsequent events and
transactions that occurred after the balance sheet date up to the date the financial statements was available
to be issued. Based upon the review, the Company did not identify any subsequent events that would have required adjustment or
disclosure in the financial statement other than the following:
On
October 14, 2022, Company issued a press release announcing that the Company has deposited into the Company’s trust account
(the “Trust Account”) an aggregate of $383,333, representing $0.033 per public share of the Company, in order to extend
the period of time the Company has to consummate a business combination by one month to November 15, 2022.